Microneedle Drug Delivery CRO/CDMO
Hours: 8:30 AM–5:30 PMSales: +86 10 8928 7035Business: bd@casmn.com

ENGLISH EDITION

Addressing Microneedle Scale-Up with the RT-SMP® Room-Temperature Printing Process (Translation)

This article examines common microneedle scale-manufacturing barriers and the process strategy behind CASMN’s RT-SMP® room-temperature printing platform.

Read the original Chinese article: 微针量产困局如何破解?RT-SMP®常温印刷工艺打造"中国方案" →
Microneedle scale-up
Microneedle scale-up. Image from the original Chinese report.

This article considers manufacturing scale-up as a barrier between microneedle research and practical product development. CASMN presents RT-SMP® room-temperature printing as its process approach to that problem.

Limitations of conventional preparation

The source contrasts room-temperature forming with methods involving demanding temperature conditions or trade-offs between throughput and structural precision. Different processes have different uses; the comparison is the company's process-development perspective rather than a universal ranking.

RT-SMP process illustration
RT-SMP process illustration. Image from the original Chinese report.

Three process elements

  • In-situ forming: one-sided negative pressure helps a viscous formulation fill mould microcavities at room temperature.
  • Laminar-flow tunnel drying: the source reports a processing-area rate of 432,000 cm² per hour under its stated manufacturing context.
  • Integrated preparation: solution preparation, degassing and sterilisation-related operations are described as integrated into one vessel.
Microneedle production line
Microneedle production line. Image from the original Chinese report.
Product application examples
Product application examples. Image from the original Chinese report.
Application areas
Application areas. Image from the original Chinese report.

Structures and applications

The platform supports work on dissolving and swelling polymer microneedles with adjustable structural parameters. Cosmetic, medical-device and pharmaceutical uses require separate development and regulatory assessment.

The source reports a Class II registration and manufacturing licence for a microneedle transdermal patch. That registration applies to the specified product and scope, not to every structure made by the process.